Asian Paints: 7000% returns in 17 years
Some investment propositions have the ability to make investors – both the newbie and the expert alike – stop and stare.
04 Apr, 2021
7 min read
2407 Views
2020 was a peculiar year, especially in terms of the industries that managed to flourish despite the challenges that the lockdowns and isolation measures brought to the business and market landscape.
However, it was also an incredibly exciting yet challenging year for pharmaceutical companies. While a number of pharma stocks have posted significant gains in the Indian stock markets, the performance and potential of Dr. Reddy’s Laboratories (DRRD) deserves a mention of its own accord. DRRD has shown promise not only in terms of the gains it has produced for the shareholders, but also their strategy in terms of the portfolio positioning, and the unique set of value propositions that it brings both to its stakeholders, the industries, and the end users.
So what differentiates DRRD from your regular run of the mill pharma stocks in the Indian markets, like Cipla, Sun Pharma, Aurobindo and IOL? Well, to begin with, DRRD has consistently directed a significant amount of funds towards R&D, thereby going beyond the arbitrage of supplying generic drugs beyond the borders. If you are new to the pharma industry, then it's worth understanding as to how generic and patented drugs bring profits to a company. Basically, if you have a patent over a drug, you can produce it almost exclusively for a considerable period of time - 20 years in the US for example - after which, your formula becomes a generic drug, which can be manufactured and supplied by any pharmaceutical company at much lower prices.
However, generic drugs can also bring a unique strategic value to a pharmaceutical company’s portfolio. For example, DRRD has consolidated its generic product portfolio around injectables, topicals and tablets and capsules for cardiovascular, respiratory, gastrointestinal and oncological ailments. In addition, DRRD also brings a strong focus in therapetics of pain management, pediatrics and dermatology. But what’s unique about DRRD is the company’s ability to capitalize on a significant length of the value chain - that is, from the manufacturing of ingredients, all the way to the end user. In addition to leveraging a strong and robust supply chain. DRRD also brings a proprietary know-how around the global regulatory compliance landscape, thereby giving it a competitive and early mover advantage through faster time to market and quality-assured products.
In 2018, DRRD was trading right below Rs. 2000, but was also known for leading investments in research and development of proprietary formulas. In 2020, the stock was trading somewhere around Rs 5200 - posting more than 150% gains over the course of two years. In addition, a tie up with Sputnik V for the production of the COVID-19 vaccine which has been postulated as a formula with zero foreseeable side effects in the long run is likely to give a significant boost to the brand, and pave the way for new partnerships too. But this is not all - DRRD’s advantageous position is actually a result of the benefits it can deliver to the end user, and the consequent ability to thrive in markets where competitive pricing pressures from the regulator are on the rise.
In terms of domestic competition, DRRD has been faring well. During the first quarter of 2021, DRRD clocked a net profit margin of over 11% - which is much higher compared to the negative profit levels of most of its direct competitors. Moreover, the company has been aggressively paying off its debts - as a result, its balance sheets look much healthier than most competitors, and this has made it an attractive investment that now stands associated with relatively lower risk levels.
However, there’s no such thing as an eternal green signal in the stock market, and each investment avenue associated with a business comes with its own set of risks and pitfalls. In the pharmaceutical sector, these risks might manifest in rather peculiar ways. For example, DRRD is not the only company that is in the race to obtain FDA approvals - this can significantly hamper the first mover advantage. The same goes for patents and compliance approvals of manufacturing facilities (DRRD was in the process of getting approvals in its API manufacturing plant in New York) - delays and hurdles in these procedures can take projects off their budgets and schedules. And lastly, counterfeit drugs and regulator’s bans following audit checks can also cost big pharma's billions of dollars. However, in terms of the latter, DRRD enjoys a unique position that can minimize the risk of counterfeit production as a result of its presence in the active ingredient supply chain and strong synergies with practitioners in the US and Europe.
There is further news too. After a settlement on a patent violation case with a company named Celgene, DRRD will obtain clearance for manufacturing and selling a cancer drug that is used to treat myeloma - a type of blood cancer. However, DRRD will be cleared to sell this anti-cancer drug in limited amounts starting around the same time in 2022, while the restrictions will be lifted by 2026. These are some long term prospects that make DRRD an appealing investment for those looking to bet on the pharmaceutical industry following last year's rally. Whether DRRD will outperform its competitors in the short and the long run is a question that only time will answer.
Looking for market intelligence that can help you make informed decisions with your investments? Then don’t miss a beat, keep yourself at the top of the game! Log on to www.angelbroking.com, and check out our other resources and reports on the happenings of the stock markets.
How would you rate this blog?
Related Blogs
Translate the power of knowledge into action. Open Free* Demat Account
Latest Blog
-
13 Oct, 2021
6 min read
LIC Seeks to Appoint CFO
According to a notice on its website, the state-owned Life Insurance Corporation of India (LIC) is looking for a Chief Financial Officer ahead of an …
-
30 Aug, 2021
7 min read
Should you Invest in the Latest Sovereign...
For the uninitiated, sovereign gold bonds can be understood to be certificates issued and mandated by the Reserve Bank of India.
-
01 Apr, 2021
7 min read
Vodafone-Idea: What went wrong?
Mergers and acquisitions can turn the eyes of stock market investors towards the possible action that such large-scale actions can bring to the futur…
-
28 Dec, 2020
6 min read
The Rise of Reliance: as told through its stocks
Reliance Industries Limited (RIL) is India’s largest publicly traded company. Read on to know more about history of Reliance stocks and it’s rise in …
-
10 Mar, 2021
7 min read
PVR - a comeback on the cards?
Who doesn’t like to watch movies. But when the COVID pandemic first hit the Indian subcontinent, investors began to withdraw from their investments -…
-
07 Jul, 2021
10 min read
Ixigo IPO: Ixigo Plans a 750 Crore IPO
Ixigo is a travel portal and it plans to host an IPO of between Rs 1500 crore to Rs 1800 crore later this year.
-
24 Feb, 2021
7 min read
Shree Cements: A lesson in Prudence
This article will help you take a deeper look into the rise of Shree Cements, through the lens of it’s stock performance over the past few years.
-
09 Jul, 2021
9 min read
IPO Alert! Devyani International files...
Against all odds, the Indian market, despite a minor tailspin due to the nationwide lockdowns last year, has seemed to recover relatively well.
-
08 Jul, 2021
10 min read
The Success Story of Pharmeasy
Today, PharmEasy is a reputable and well-known firm whose aim is to become the best health care delivery platform in India.
-
06 Oct, 2021
5 min read
Byju’s IPO Plans
Currently, India's most valuable unicorn, online education provider Byju's, is in talks to raise $400 million to $600 million and then expedite plans…
-
06 Jan, 2021
6 min read
Tata Consultancy Services: A story...
Tata Consultancy Services (TCS) is the world’s most valuable IT company. Read this success story of how TCS expanded globally, acquired new verticals…
-
15 May, 2021
8 min read
The Best Penny Stocks in India
Investing and trading on the stock market has the potential to generate profits.
-
08 May, 2021
8 min read
Adani Ports and its recent rise. Here's why
If you have been following the rise of Adani Ports’ stock price in recent weeks, you are probably curious as to what is driving this growth.
-
27 Jan, 2021
9 min read
HDFC Bank Ltd’s Journey to becoming the...
As of November 25, 2020, HDFC Bank had hit a market cap of ₹8 Lakh Crore and had become the third company to do so after Reliance and TCS.
-
16 Mar, 2021
8 min read
Indiamart’s QIP: behind the scenes
Last year, when the pandemic had hit businesses hard across the globe, most people resorted to the internet to keep their businesses afloat.
-
11 Jun, 2021
7 min read
Stock Picks Based on Q4 Results
As FY21 drew to a close, it was a déjà vu moment as lockdowns (although state-level), and a second wave of the COVID-19 pandemic defined investor beh…
-
13 Jun, 2021
7 min read
Soaring commodity prices. Here's why
Prices of commodities in the energy, metal and agriculture sectors have seen a sustained rise in the first few months of this year.
-
07 Apr, 2021
7 min read
The Tata Motors Upheaval Story
The automotive industry has been famously tied to the performance of the extended economy for most countries.
-
06 May, 2021
9 min read
Should you place your bets on ITC?
Investors trading on the stock market are advised to focus on maximising their wealth by making shrewd decisions based on the performance and fundame…
-
05 Mar, 2021
7 min read
The LIC IPO Game Plan
IPOs have attracted overt attention of retail and institutional investors alike in the recent Indian stock market scene.
-
23 Jul, 2021
8 min read
Laurus Labs Share: More than 50% Return...
Shares of pharmaceutical and biotech company Laurus Labs have continued to surge upwards and have hit a new high amounting to INR 599 per share on th…
-
15 Jun, 2021
10 min read
A sneak peek at Zomato's IPO plans
Covid-19 came and turned the world upside down – tourism, airlines, fashion, F&B have suffered tremendously but online financial gateways, video conf…
-
24 Aug, 2021
5 min read
Stocks to Watch: NMDC, Tata Motors,...
This article seeks to shed light on stocks that have recently been made available in the market. Included among them is the government’s stake in NMD…
-
23 Aug, 2021
6 min read
Clean Science, GR Infraprojects IPO...
This article seeks to shed light on initial public offerings (or IPOs) that have recently been up for grabs in the market. Included among them are Cl…
-
03 Jun, 2021
6 min read
Hotel Stocks on the Rise Despite Lockdown
The hospitality industry suffered a major setback when the prime minister announced a nationwide lockdown for 3 weeks at the end of March 2020.
-
31 May, 2021
7 min read
The Rise of Metal Stocks Amid the 2nd Wave
The past few months have brought with them several changes.
-
29 Oct, 2021
7 min read
Sugar Stocks Down as Sensex Falls
Sugar stocks are indicative of important trends in the market. They are also an important cog in the industries sector of the economy. Read on to kno…
-
01 Jun, 2021
8 min read
Muted Tata Communications stock in wake...
There is a meme going around that says: Sneezes went from “Bless you” to “To hell with you” real soon.
-
05 Oct, 2021
7 min read
LIC IPO: All we Know So Far
While investors await the Life Insurance Corporation's mammoth public offering mostly happening this financial year, why do experts think the IPO has…
-
24 Sep, 2021
7 min read
Indian Railways Share Quarterly Results -...
The Indian Railway Catering and Tourism Corporation (IRCTC) is a subsidiary of the Indian Railways.
-
11 Jul, 2021
11 min read
Go Air IPO: Go Air looks to enter the IPO market
GoAir, one of India’s most popular airlines, is preparing for an initial public offering (IPO). Rebranding itself as “Go First”, the airline filed a …
Ready To Trade? Start with
Subscribe to #SmartSauda Newsletter
CONTINUE WITH GOOGLE
CONTINUE WITH FACEBOOK
